Hydroxyzine is an antihistamine sold under brand names such as Atarax and Vistaril, and it is commonly prescribed for anxiety, itching from allergic skin reactions, nausea, and as a sedative before or after a procedure. Because it is prescribed for anxiety, some employees assume it will trigger a positive drug test the same way a benzodiazepine might. That assumption is generally wrong. Hydroxyzine is not a controlled substance, and it is not one of the substances a standard workplace urine panel is built to detect. What employers and employees should understand instead is a narrower, well documented laboratory issue: hydroxyzine and its active metabolite have been shown in published research to interfere with certain immunoassay tests for tricyclic antidepressants, which can produce a misleading screening result that confirmation testing resolves.
What hydroxyzine is and how it is used
Hydroxyzine is classified as an antihistamine, and it is used to treat itching from allergies, to relieve anxiety and tension, and as a sedative in combination with other medications before and after surgery, according to the National Institutes of Health consumer drug reference at MedlinePlus. It commonly causes drowsiness, and the labeling for hydroxyzine products warns against driving or operating machinery until a person knows how the medication affects them, and against combining it with alcohol, which can worsen sedation. Full prescribing information, including warnings and the approved uses for hydroxyzine products currently on the market, is available through the National Library of Medicine's DailyMed label database.
Is hydroxyzine a controlled substance?
No. Hydroxyzine is not scheduled under the federal Controlled Substances Act, unlike benzodiazepines such as alprazolam or diazepam, which are Schedule IV. That distinction matters for drug testing because standard panels are built around federally scheduled and commonly misused substances. Hydroxyzine's anxiety indication sometimes leads people to lump it in with prescription anxiety medications that are controlled, but pharmacologically and legally it is a different class of drug, and it does not carry the same diversion or abuse potential that scheduling addresses.
What standard drug test panels actually screen for
The federal five panel used in safety sensitive and many workplace testing programs targets marijuana metabolites, cocaine metabolites, opiates, phencyclidine, and amphetamines. The specific analytes and cutoff levels for this panel are set out in the Department of Transportation's testing regulation at 49 CFR 40.85. Extended workplace panels, often marketed as 10 panel, 12 panel, or larger configurations, add classes such as benzodiazepines, barbiturates, methadone, and in some configurations a tricyclic antidepressant (TCA) screen. Antihistamines, including hydroxyzine and diphenhydramine, are not a named analyte class on any of these standard immunoassay panels. A general overview of which drug classes standard immunoassay panels are designed to catch, and how confirmation testing works, is available in the NCBI Bookshelf StatPearls chapter on drug testing.
| Panel type | Typical analyte classes | Targets hydroxyzine directly |
|---|---|---|
| Federal five panel (DOT, SAMHSA-style) | THC, cocaine, opiates, PCP, amphetamines | No |
| Extended 10 to 12 panel workplace cup | Adds benzodiazepines, barbiturates, methadone, and sometimes TCA | No, but the TCA line can cross react |
| Broad prescription medication or toxicology panel (LC-MS/MS ordered by name) | Can be built to include specific antihistamines | Yes, if specifically ordered and validated for that analyte |
The tricyclic antidepressant false positive issue
The more relevant concern with hydroxyzine is not that it will be flagged as an antihistamine, but that it can interfere with the immunoassay used to screen for tricyclic antidepressants (TCAs) on some testing platforms. A laboratory study published in a peer reviewed clinical chemistry journal and indexed on PubMed found that hydroxyzine and its active metabolite, cetirizine, produced apparent tricyclic antidepressant concentrations on a fluorescence polarization immunoassay when added to drug free serum at levels consistent with typical to elevated dosing. The same study found no meaningful interference with a different immunoassay platform for carbamazepine, which illustrates a broader point about this kind of interference: it depends heavily on the specific assay chemistry and instrument a laboratory uses, not on the drug alone. The NCBI Bookshelf StatPearls chapter on clinical drug testing separately notes that other antihistamines, including diphenhydramine, are recognized causes of false positive results on TCA immunoassays, which supports the idea that this is a class effect tied to how these molecules interact with certain antibody based tests rather than something unique to one brand name product.
Two things are worth being precise about. First, most of the published interference data involves serum based immunoassays used in clinical and therapeutic drug monitoring settings, not the urine immunoassay cups used in typical pre-employment or random workplace testing, so the practical frequency of this exact problem on a workplace urine TCA screen is not well established and likely varies by lab and platform. Second, a screening immunoassay is never the final word on any drug class. Any positive TCA screen, whatever the suspected cause, is expected to be confirmed with a chromatographic method such as gas chromatography or liquid chromatography coupled to mass spectrometry before it is treated as a true positive.
Why confirmation testing exists for exactly this reason
Immunoassay screening tests are fast and inexpensive, but they work by detecting whether a molecule binds to an antibody, and molecules with a similar structure to the target drug can sometimes bind well enough to trigger a positive signal even when the actual target substance is absent. This is true across several drug classes, not just TCAs, which is why every accredited testing program treats an immunoassay screen as presumptive rather than final. A specimen that screens positive is retested using a definitive chromatographic and mass spectrometry method that can distinguish hydroxyzine or its metabolite from an actual tricyclic antidepressant at the molecular level. This screen and confirm structure is described in the StatPearls chapter on clinical drug testing, and it is the same reason a person taking an over the counter antihistamine like diphenhydramine should never be treated as having a confirmed drug test violation based on a screening result alone. For background on how a different common antihistamine interacts with drug testing, see our related post on Benadryl and diphenhydramine false positives, and for a broader look at how the TCA panel itself works, see our post on the tricyclic antidepressant drug test.
What an employee taking hydroxyzine should do
An employee who takes hydroxyzine, whether for anxiety, allergies, or as directed after a medical procedure, does not need to disclose it in advance in most cases, since it is not a screened for substance on standard panels. If a screening result does come back positive for a class such as TCA, opiates, or any other panel and the employee believes a medication is responsible, the correct step is to provide accurate information about current prescriptions and over the counter medications to the medical review officer during the verification call, along with documentation if requested. Employees should not attempt to guess at or self diagnose why a result came back a certain way, and they should never take steps intended to alter, dilute, or interfere with a specimen, since that carries its own serious consequences separate from the underlying test result.
What employers should keep in mind
- Hydroxyzine is not a controlled substance and is not a named analyte on the federal five panel or on most standard extended workplace panels.
- Published laboratory research shows hydroxyzine and its metabolite can interfere with certain tricyclic antidepressant immunoassays, an issue that is platform dependent rather than universal.
- A presumptive positive screening result, whatever the drug class, is never a final determination. Confirmation by a chromatographic and mass spectrometry method is the standard that resolves cross reactivity questions.
- Only a qualified medical review officer should evaluate a confirmed positive result against an employee's reported medications, and employers should not make employment decisions based on an unconfirmed screening result alone.
- State laws and individual employer policies on medication disclosure and adverse action vary, so employers should apply a written policy consistently and consult qualified counsel on specific cases.
Frequently asked questions
Does hydroxyzine show up as a positive on a standard drug test?
Generally no. Hydroxyzine is an antihistamine, and standard federal five panel and most extended workplace panels are not built to detect antihistamines as a class.
Is hydroxyzine a controlled substance like a benzodiazepine?
No. Hydroxyzine is not scheduled under the federal Controlled Substances Act, even though it is sometimes prescribed for anxiety the way a benzodiazepine might be. It is pharmacologically a different class of medication.
Can hydroxyzine cause a false positive drug test result?
Published laboratory research has shown that hydroxyzine and its active metabolite can interfere with certain immunoassay tests for tricyclic antidepressants on some testing platforms, which can produce a misleading screening result. This is not universal across all assay types and is not the same as hydroxyzine itself being detected as a drug of abuse.
Will a lab specifically test for hydroxyzine unless it is ordered by name?
Typically not. Standard immunoassay panels are not configured to identify hydroxyzine specifically. A broader prescription medication or toxicology panel using chromatography and mass spectrometry can be built to detect it if a lab specifically validates and orders that analyte.
What should an employee do if a positive result might be related to a medication?
Report current prescriptions and over the counter medications accurately to the medical review officer during the verification process and provide documentation if asked. The MRO, not the employer, determines whether a confirmed result has a legitimate medical explanation.
Does a positive TCA screen always mean tricyclic antidepressant use?
No. A positive TCA immunoassay screen is presumptive and can be affected by cross reacting substances. Confirmation testing using chromatography and mass spectrometry is required before a result should be treated as verified.
Employers who need reliable cups configured to standard panel cutoffs can review our drug test cup collection.
This article is general information, not legal or medical advice. Testing rules, panel configurations, and state laws vary, and employers and employees should consult qualified counsel and a medical review officer for specific cases.
